IDEAYA Biosciences to Participate in Investor Conferences in September 2022

SOUTH SAN FRANCISCO, Calif., Aug. 30, 2022 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a synthetic lethality focused precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced its participation in investor conferences and events in September 2022.

Citi's 17^th Annual BioPharma Conference
September 7-8, 2022

Wells Fargo Healthcare Conference
September 7-9, 2022

Morgan Stanley 20^th Annual Global Healthcare Conference
September 12-14, 2022
Monday, September 12 at 4:15pm ET
     Fireside chat with Yujiro Hata, Chief Executive Officer, IDEAYA Biosciences, hosted by Ashwin Pai, M.D. Managing Director

Baird 20^th 2022 Global Healthcare Conference
September 13-14, 2022
Wednesday, September 14 at 9:05am ET
     Corporate Presentation by Paul Stone, Chief Financial Officer, IDEAYA Biosciences

Oppenheimer's Oncology Summit / University of Texas MD Anderson Cancer Center
September 21, 2022

Cantor Oncology, Hematology & HemOnc Conference
September 28, 2022
Wednesday, September 28
     Panel: "Novel Targets in Oncology: Risk vs. Reward", with participation by Mike White, Chief Scientific Officer, IDEAYA Biosciences

A live audio webcast of the event will be available, as permitted by conference host, at the "Investors/News and Events/Investor Calendar" section of the IDEAYA website at https://ir.ideayabio.com/events.  A replay of available webcasts will be accessible for 30 days following the live event.

About IDEAYA Biosciences
IDEAYA is a synthetic lethality-focused precision medicine oncology company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics.  IDEAYA's approach integrates capabilities in identifying and validating translational biomarkers with drug discovery to select patient populations most likely to benefit from its targeted therapies.  IDEAYA is applying its early research and drug discovery capabilities to synthetic lethality – which represents an emerging class of precision medicine targets. 

Forward-Looking Statements
This press release contains forward-looking statements, including, but not limited to, statements related to participation in and/or presentation at certain investor relations events. IDEAYA undertakes no obligation to update or revise any forward-looking statements. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of IDEAYA in general, see IDEAYA's Quarterly Report on Form 10-Q filed on August 15, 2022 and any current and periodic reports filed with the U.S. Securities and Exchange Commission.

SOURCE IDEAYA Biosciences, Inc.